Skip Navigation


JAC Advance Access originally published online on June 21, 2005
Journal of Antimicrobial Chemotherapy 2005 56(2):337-343; doi:10.1093/jac/dki198
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/2/337    most recent
dki198v2
dki198v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gander, S.
Right arrow Articles by Finch, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gander, S.
Right arrow Articles by Finch, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Telavancin: in vitro activity against staphylococci in a biofilm model

Sarah Gander, Andrew Kinnaird and Roger Finch*

Division of Microbiology and Infectious Diseases, Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Nottingham NG5 1PB, UK

Received 13 May 2005; accepted 20 May 2005

* Corresponding author. Tel: +44-115-840-4741; Fax: +44-115-840-4742; E-mail: r.finch{at}nottingham.ac.uk

Objectives: To assess the in vitro activity of the novel lipoglycopeptide telavancin against staphylococcal biofilms using an in vitro pharmacokinetic model.

Methods: Using the Sorbarod model, biofilms were established. The strains tested included methicillin-susceptible and -resistant strains of Staphylococcus aureus and coagulase-negative staphylococci, as well as glycopeptide-intermediate S. aureus (GISA). The biofilms were exposed to exponentially decreasing concentrations of telavancin and four comparator antibiotics, vancomycin, teicoplanin, linezolid and moxifloxacin and the bactericidal activity of the antibiotics was assessed. The concentrations of the antibiotics used in these experiments corresponded to peak serum levels achievable in humans and the rates at which drug concentrations were decreased corresponded to their elimination half-lives.

Results: All of the drugs tested produced a reduction in the number of bacteria eluted from the biofilms. Telavancin was more effective than the commercially available glycopeptides, vancomycin and teicoplanin, and of the three, was the most active agent against both the non-GISA and GISA strains. Of all the antibiotics tested, moxifloxacin produced the greatest reduction in biofilm cells, but only against the non-GISA strains.

Conclusions: Telavancin exhibited substantial antimicrobial activity against staphylococcal biofilms, including GISA strains. This study supports the case for the evaluation of telavancin in the treatment of staphylococcal biofilm-associated infections.

Keywords: pharmacokinetic models , glycopeptides , GISA , indwelling medical devices


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. N. Leonard, C. Vidaillac, and M. J. Rybak
Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2928 - 2933.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. LaPlante and L. A. Mermel
In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3166 - 3169.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. O. Darouiche, M. D. Mansouri, and M. J. Schneidkraut
Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2626 - 2628.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. Charneski, P. N Patel, and D. Sym
Telavancin: A Novel Lipoglycopeptide Antibiotic
Ann. Pharmacother., May 1, 2009; 43(5): 928 - 938.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. L. Wong, S. L. Barriere, M. M. Kitt, and M. R. Goldberg
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects
J. Antimicrob. Chemother., October 1, 2008; 62(4): 780 - 783.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. J. Attwood and K. L. LaPlante
Telavancin: A novel lipoglycopeptide antimicrobial agent
Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. Odenholt, E. Lowdin, and O. Cars
Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3311 - 3316.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. M. Miro, C. Garcia-de-la-Maria, Y. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, et al.
Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2373 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Barcia-Macay, S. Lemaire, M.-P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke
Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1177 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. D. Leuthner, C. M. Cheung, and M. J. Rybak
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus
J. Antimicrob. Chemother., August 1, 2006; 58(2): 338 - 343.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.